Invega application withdrawn in EU for bipolar disorder
This article was originally published in Scrip
Executive Summary
Janssen-Cilag(Johnson & Johnson) has withdrawn its EU application for an extension of indication for Invega (paliperidone) prolonged-release tablets to treat acute manic episodes associated with bipolar I disorder.